睿知中国医院研究地图
候选清单

即将招募肝细胞癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  2. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07823348,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically/cytologically confirmed HCC, or cirrhosis meeting the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC.

    入选标准第 3 条

  3. Child-Pugh liver function grade A or grade B with a score ≤7, and no history of hepatic encephalopathy.

    入选标准第 6 条

  4. Prior treatment-related toxicity not recovered to ≤ CTCAE Grade 1.

    排除标准第 2 条

    Known history of human immunodeficiency virus (HIV) infection, prior allogeneic stem cell or solid organ transplantation, or other immunodeficiency.

    排除标准第 14 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.

    入选标准第 7 条

  6. At least one measurable lesion per RECIST v1.1 criteria.

    入选标准第 5 条

  7. Malignancy other than HCC within 5 years prior to the first dose.

    排除标准第 10 条

  8. Female participants of childbearing potential and male participants with female partners of childbearing potential must use a highly effective contraceptive method during the study and for at least 6 months after the last dose. Female participants of childbearing potential must have a negative blood HCG test within 7 days prior to study enrollment and must not be breastfeeding.

    入选标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07823348,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily participate and sign a written informed consent form.
  2. Aged 18-75 years, regardless of sex.
  3. Histologically/cytologically confirmed HCC, or cirrhosis meeting the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC.
  4. No prior systemic therapy for HCC.
  5. At least one measurable lesion per RECIST v1.1 criteria.
  6. Child-Pugh liver function grade A or grade B with a score ≤7, and no history of hepatic encephalopathy.
  7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
  8. Expected survival ≥ 12 weeks.
  9. Adequate hematologic and end-organ function.
  10. Female participants of childbearing potential and male participants with female partners of childbearing potential must use a highly effective contraceptive method during the study and for at least 6 months after the last dose. Female participants of childbearing potential must have a negative blood HCG test within 7 days prior to study enrollment and must not be breastfeeding.

排除标准:Exclusion Criteria:

  1. Concomitant with the following study disease states: Known intrahepatic cholangiocarcinoma (ICC) or mixed-type liver cancer, sarcomatoid hepatocellular carcinoma, and fibrolamellar carcinoma of the liver; Presence of HCC central nervous system metastasis.
  2. Prior treatment-related toxicity not recovered to ≤ CTCAE Grade 1.
  3. Severe infection at screening.
  4. Uncontrolled pericardial effusion, uncontrolled pleural effusion, or clinically apparent moderate or greater ascites at screening.
  5. Severe unhealed wounds, active ulcers, or untreated fractures at screening.
  6. Severe cardiovascular or cerebrovascular disease:
  7. History of gastrointestinal bleeding within 6 months prior to the first dose, or definite tendency for gastrointestinal bleeding.
  8. Other obvious bleeding tendency or evidence of major coagulation disorders:
  9. Active autoimmune disease requiring systemic treatment within 2 years prior to the first dose.
  10. Malignancy other than HCC within 5 years prior to the first dose.
  11. Confirmed or suspected moderate-to-severe pulmonary disease severely affecting pulmonary function.
  12. Active tuberculosis.
  13. Co-infection with hepatitis B and hepatitis C.
  14. Known history of human immunodeficiency virus (HIV) infection, prior allogeneic stem cell or solid organ transplantation, or other immunodeficiency.
  15. Known history of severe allergy to any monoclonal antibody.
  16. Other factors that, in the investigator's judgment, may affect study results or lead to forced premature termination of the study.

引自 ClinicalTrials.gov, NCT07823348, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07823348,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07823348